Hunan Hansen Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
Hunan Hansen Pharmaceutical has been growing earnings at an average annual rate of 8.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.5% per year. Hunan Hansen Pharmaceutical's return on equity is 10.8%, and it has net margins of 23.4%.
Key information
8.8%
Earnings growth rate
8.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.5% |
| Return on equity | 10.8% |
| Net Margin | 23.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Hunan Hansen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 965 | 226 | 416 | 42 |
| 30 Jun 24 | 964 | 215 | 435 | 42 |
| 31 Mar 24 | 959 | 208 | 459 | 40 |
| 31 Dec 23 | 956 | 205 | 457 | 44 |
| 30 Sep 23 | 919 | 147 | 450 | 45 |
| 30 Jun 23 | 925 | 179 | 457 | 46 |
| 31 Mar 23 | 917 | 171 | 443 | 52 |
| 01 Jan 23 | 916 | 168 | 450 | 48 |
| 30 Sep 22 | 913 | 151 | 465 | 46 |
| 30 Jun 22 | 911 | 143 | 451 | 45 |
| 31 Mar 22 | 905 | 141 | 448 | 42 |
| 01 Jan 22 | 892 | 135 | 451 | 39 |
| 30 Sep 21 | 879 | 135 | 464 | 36 |
| 30 Jun 21 | 873 | 124 | 466 | 36 |
| 31 Mar 21 | 802 | 115 | 417 | 32 |
| 31 Dec 20 | 741 | 106 | 382 | 31 |
| 30 Sep 20 | 788 | 144 | 360 | 35 |
| 30 Jun 20 | 780 | 144 | 343 | 33 |
| 31 Mar 20 | 848 | 159 | 394 | 30 |
| 31 Dec 19 | 887 | 162 | 409 | 33 |
| 30 Sep 19 | 881 | 164 | 463 | 29 |
| 30 Jun 19 | 913 | 159 | 484 | 33 |
| 31 Mar 19 | 910 | 151 | 471 | 38 |
| 31 Dec 18 | 922 | 148 | 471 | 36 |
| 30 Sep 18 | 896 | 129 | 441 | 34 |
| 30 Jun 18 | 864 | 116 | 417 | 43 |
| 31 Mar 18 | 857 | 116 | 419 | 32 |
| 31 Dec 17 | 830 | 109 | 418 | 25 |
| 30 Sep 17 | 832 | 90 | 442 | 19 |
| 30 Jun 17 | 831 | 88 | 458 | 0 |
| 31 Mar 17 | 814 | 86 | 445 | 0 |
| 31 Dec 16 | 798 | 85 | 439 | 0 |
| 30 Sep 16 | 796 | 90 | 444 | 0 |
| 30 Jun 16 | 787 | 95 | 437 | 0 |
| 31 Mar 16 | 793 | 98 | 429 | 0 |
| 31 Dec 15 | 781 | 98 | 418 | 0 |
| 30 Sep 15 | 772 | 106 | 404 | 0 |
| 30 Jun 15 | 749 | 115 | 374 | 0 |
| 31 Mar 15 | 734 | 114 | 372 | 0 |
| 31 Dec 14 | 737 | 118 | 371 | 0 |
| 30 Sep 14 | 676 | 119 | 326 | 0 |
| 30 Jun 14 | 643 | 118 | 312 | 0 |
| 31 Mar 14 | 616 | 118 | 305 | 0 |
| 31 Dec 13 | 585 | 111 | 303 | 0 |
Quality Earnings: 002412 has high quality earnings.
Growing Profit Margin: 002412's current net profit margins (23.4%) are higher than last year (16%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002412's earnings have grown by 8.8% per year over the past 5 years.
Accelerating Growth: 002412's earnings growth over the past year (53.5%) exceeds its 5-year average (8.8% per year).
Earnings vs Industry: 002412 earnings growth over the past year (53.5%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 002412's Return on Equity (10.8%) is considered low.